TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB: “BVTI”), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”), announced that the National Cancer Institute (NCI) presented long-term (11-year) outcome data from its BiovaxID® Phase II clinical trial conducted in collaboration jointly with the NCI at the 2011 Annual Meeting of the American Society of Hematology (ASH 2011). The results (detailed in Abstract #2707), reported by a Senior Investigator from the NCI, demonstrated that vaccination with BiovaxID active immunotherapy following rituximab combination chemotherapy induced nearly universal immune responses which strongly correlated with overall survival (OS) in treated patients. These immune responses, moreover, primarily consisted of tumor-specific T-cell immune responses which complemented the effects of induction rituximab chemotherapy in a highly aggressive non-Hodgkin’s lymphoma, mantle cell lymphoma (MCL).
